title: [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
abstract: We prospectively studied the usefulness of chlormadinone acetate (CMA) as an alternative therapy for prostate cancer relapse after combined androgen blockade (CAB) therapy. Sixteen patients with relapsed prostate cancer after treatment with CAB, including surgical or medical castration and nonsteroidal antiandrogens, 80 mg bicalutamide daily or 375 mg flutamide daily, were enrolled. After discontinuing the antiandrogen for evaluating the patient for the antiandrogen withdrawal syndrome, we administered 100 mg CMA daily as alternative antiandrogen and estimated its effect. Four patients showed a > or = 50% decline in prostate-specific antigen (PSA) levels and another 4 patients showed a < 50% decline in PSA levels but residual 8 patients showed no decline in PSA levels. In 8 patients with a decline in PSA levels, the median duration of alternative CMA therapy was 11.4 months. Patients with a PSA level of < 1 ng/ml at the start of CMA therapy showed the tendency of decline in PSA levels. In contrast, patients with a nadir PSA level of > or = 0.2 ng/ml during pretreatment showed no effectiveness of the alternative CMA therapy. The alternative CMA therapy may be useful in a part of patients with prostate cancer relapse after CAB therapy.
authors.affiliation: Department of Urology, Gifu University Hospital.
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Ehara
authors.forename: Seichi
authors.initials: S
authors.lastname: Katoh
authors.forename: Keita
authors.initials: K
authors.lastname: Nakane
authors.forename: Taku
authors.initials: T
authors.lastname: Katoh
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Takada
authors.forename: Keitaro
authors.initials: K
authors.lastname: Kojima
authors.forename: Shingo
authors.initials: S
authors.lastname: Kamei
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Hagiwara
authors.forename: Kazuya
authors.initials: K
authors.lastname: Yuhara
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujihiro
authors.forename: Yuhsuke
authors.initials: Y
authors.lastname: Kanimoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002715:Chlormadinone Acetate / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D002715:Chlormadinone Acetate